Predictive role of HER-2/neu overexpression and clinical features at initial presentation in patients with extensive stage small cell lung carcinoma

Minna, 1989, Cancer of the lung, 591 Parker, 1996, Cancer statistics, 1996, CA Cancer J. Clin., 65, 5, 10.3322/canjclin.46.1.5 Di Loreto, 1997, Immunocytochemical expression of tissue specific transcription factor-1 in lung carcinoma, J. Clin. Pathol., 50, 30, 10.1136/jcp.50.1.30 Boring, 1994, Cancer statistics, 1994, CA Cancer J. Clin., 44, 7, 10.3322/canjclin.44.1.7 Hoffman, 2000, Lung cancer, Lancet, 355, 479, 10.1016/S0140-6736(00)82038-3 Lassen, 1995, Long-term survival in small-cell lung cancer: posttreatment characteristics in patients surviving 5 to 18+ years—an analysis of 1,714 consecutive patients, J. Clin. Oncol., 13, 1215, 10.1200/JCO.1995.13.5.1215 Chute, 1997, Outcome of patients with small-cell lung cancer during 20 years of clinical research at the US National Cancer Institute, Mayo Clin. Proc., 72, 901, 10.4065/72.10.901 Hung, 1999, Basic science of HER-2/neu: a review, Semin. Oncol., 26, 51 Schneider, 1989, Differential expression of the c-erbB-2 gene in human small cell and non-small cell lung cancer, Cancer Res., 49, 4968 Weiner, 1990, Expression of neu gene-encoded protein (P185neu) in human non-small cell carcinomas of the lung, Cancer Res., 50, 421 Zhang, 1989, Amplification and rearrangement of c-erbB proto-oncogenes in cancer of human female genital tract, Oncogene, 4, 985 Yokota, 1988, Genetic alterations of the c-erbB-2 oncogene occur frequently in tubular adenocarcinoma of the stomach and are often accompanied by amplification of the v-erbA homologue, Oncogene, 2, 283 Riben, 1997, Identification of HER-2/neu oncogene amplification by fluorescence in situ hybridization in stage I endometrial carcinoma, Mod. Pathol., 10, 823 Costa, 1996, Epidermal growth factor receptor and c-erbB-2 oncoprotein expression in female genital tract carcinosarcomas (malignant mixed Mullerian tumors). Clinicopathologic study of 82 cases, Cancer, 77, 535, 10.1002/(SICI)1097-0142(19960201)77:3<533::AID-CNCR16>3.0.CO;2-5 Dugan, 1997, HER-2/neu expression in pancreatic adenocarcinoma: relation to tumor differentiation and survival, Pancreas, 14, 229, 10.1097/00006676-199704000-00003 Kapitanovic, 1997, The expression of p185 (HER-2/neu) correlates with the stage of disease and survival in colorectal cancer, Gastroenterology, 112, 1103, 10.1016/S0016-5085(97)70120-3 Costa, 1995, C-erbB-2 oncoprotein over-expression in uterine cervix carcinoma with glandular differentiation. A frequent event but not an independent prognostic marker because it occurs late in the disease, Am. J. Clin. Pathol., 104, 634, 10.1093/ajcp/104.6.634 Mellemgaard, 1994, Risk of kidney cancer and other second solid malignancies in patients with chronic lymphocytic leukemias, Eur. J. Haematol., 53, 218, 10.1111/j.1600-0609.1994.tb00192.x Jimenez, 2000, Determination of HER-2/neu status in breast carcinoma: comparative analysis of immunohistochemistry and fluorescent in situ hybridization, Mod. Pathol., 13, 37, 10.1038/modpathol.3880007 Bluehler, 2000, Effective HER-2/neu diagnosis in breast cancer by a combination of immunochemistry and FISH, Proc. Am. Soc. Clin. Oncol., 19, 76a Mass, 2000, The concordance between the clinical trials assay (CTA) and fluorescence in situ hybridization (FISH) in the Herceptin pivotal trials, Proc. Am. Soc. Clin. Oncol., 19, 75a Kaplan, 1958, Nonparametric estimation from incomplete observations, J. Am. Stat. Assoc., 53, 457, 10.2307/2281868 Feinstein, 1985, The Will Rogers phenomenon. Stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer, New Engl. J. Med., 312, 1604, 10.1056/NEJM198506203122504 Dearing, 1990, Outcome of patients with small cell lung cancer: effect of changes in staging procedures and imaging technology on prognostic factors over 14 years, J. Clin. Oncol., 8, 1042, 10.1200/JCO.1990.8.6.1042 Paesmans, 2000, Prognostic factors for patients with small cell lung carcinoma, Cancer, 89, 523, 10.1002/1097-0142(20000801)89:3<523::AID-CNCR7>3.0.CO;2-6 Lebeau, 1995, Chimiothérapie des cancers bronchiques à petites cellules. Impotence dune réponse complete (1,280 patients), Pres. Med., 24, 217 Sporn, 1985, Autocrine growth factors and cancer, Nature, 313, 747, 10.1038/313745a0 Masui, 1984, Growth inhibition of human tumor cells in athymic mice by anti-epidermal growth factor receptor monoclonal antibodies, Cancer Res., 44, 1002 Cerny, 1986, Expression of epidermal growth factor receptor (EGF-R) in human lung tumors, Br. J. Cancer, 54, 265, 10.1038/bjc.1986.172 Rusch, 1995, Aberrant expression of p53 and the epidermal growth factor receptor is frequent in early bronchial neoplasia and coexpression precedes squamous cell carcinoma development, Cancer Res., 55, 1365 Bos, 1996, Phase I studies of anti-epidermal growth factor receptor (EGFR) Chimeric monoclonal antibody C225 in patients with EGFR overexpressing tumors, Proc. Am. Soc. Clin. Oncol., 15, 443 Nakanishi, 1988, Insulin like growth factor-1 can mediate autocrine proliferation of human small cell lung cancer cell line in vitro, J. Clin. Invest., 82, 354, 10.1172/JCI113594 Johnson, 1993, Overview of genetic and molecular events in the pathogenesis of lung cancer, Chest, 103, 15, 10.1378/chest.103.1.1Sb Tateishi, 1991, Prognostic value of c-erbB-2 in human lung adenocarcinoma and squamous cell carcinoma, Eur. J. Cancer, 27, 1372, 10.1016/0277-5379(91)90012-3 Arteaga, 1995, Epidermal growth factor and c-erbB-2 in human lung cancer, 107 Sloman, 1996, Immunohistochemical markers of prolonged survival in small cell carcinoma of the lung. An immunohistochemical study, Arch. Pathol. Lab. Med., 120, 465 Micke, 2001, c-erbB-2 expression in small cell lung cancer is associated with poor response, Int. J. Cancer, 92, 474, 10.1002/ijc.1229 Yoshimura, 2000, Analysis of serum erbB-2 protein and HLA-DRB1 in Japanese patients with lung cancer, Cancer Lett., 152, 87, 10.1016/S0304-3835(99)00437-1 Berchuck, 1990, Over-expression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer, Cancer Res., 50, 4087 Gusterson, 1992, Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group, J. Clin. Oncol., 10, 1049, 10.1200/JCO.1992.10.7.1049 Slamon, 1987, Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene, Science, 235, 177, 10.1126/science.3798106 Slamon, 1989, Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer, Science, 244, 707, 10.1126/science.2470152 Yu, 1998, Overexpression of both p185c-erbB-2/neu and p170mdr-1 renders breast cancer cells highly resistant to Taxol via MDR-1 independent mechanisms, Oncogene, 16, 2087, 10.1038/sj.onc.1201729 Yu, 1996, Overexpression of c-erbB-2/neu in breast cancer cells confers increased resistance to Taxol via MDR-1 independent mechanisms, Oncogene, 13, 1359 Tsai, 1993, Correlation of intrinsic chemoresistance of non-small cell lung cancer cell lines with HER-2/neu gene expression but not with ras gene mutations, J. Natl. Cancer Inst., 85, 897, 10.1093/jnci/85.11.897